“There is quite a lot going on both in terms of what we call symptomatic treatment, or treating the symptoms that people with Parkinson’s have today, as well as stopping Parkinson’s disease tomorrow — what we call disease modification,” said Irfan Qureshi, MD, as he discusses progress in Parkinson’s research on our latest Third Thursdays Webinar.
In this audio from the webinar, Michael J. Fox Foundation Chief Scientific Officer Mark Frasier, PhD, leads a discussion with expert panelists:
- Irfan Qureshi, MD, vice president of neurology at Biohaven Pharmaceuticals
- Beate Ritz, MD, PhD, professor of epidemiology, environmental health sciences and neurology at the University of California, Los Angeles
- Marion Fioretti, person with Parkinson’s and active Team Fox member
Over the hour, panelists cover approaches to stop disease, new treatment advances and work around environmental exposures linked to Parkinson’s. Want to learn more? Read our year in review publication.
Rather listen on-the-go? Subscribe to our Michael J. Fox Foundation Parkinson's Podcast on iTunes or through any podcast app on your smartphone or tablet.
